LY2140023
13560
Phase 2 small_molecule terminated
Quick answer
LY2140023 for Schizophrenia is a Phase 2 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Schizophrenia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated